{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:35:38Z","timestamp":1775151338796,"version":"3.50.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Virological Methods"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.jviromet.2009.06.015","type":"journal-article","created":{"date-parts":[[2009,6,26]],"date-time":"2009-06-26T13:37:52Z","timestamp":1246023472000},"page":"231-239","source":"Crossref","is-referenced-by-count":16,"title":["A combined genotypic and phenotypic human immunodeficiency virus type 1 recombinant virus assay for the reverse transcriptase and integrase genes"],"prefix":"10.1016","volume":"161","author":[{"given":"Kurt","family":"Van Baelen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelien","family":"Rondelez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veerle","family":"Van Eygen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Ari\u00ebn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marleen","family":"Clynhens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peggy","family":"Van den Zegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Winters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lieven J.","family":"Stuyver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jviromet.2009.06.015_bib1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0022-2836(05)80360-2","article-title":"Basic local alignment search tool","volume":"215","author":"Altschul","year":"1990","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jviromet.2009.06.015_bib2","doi-asserted-by":"crossref","first-page":"5728","DOI":"10.1128\/JVI.78.11.5728-5736.2004","article-title":"Styrylquinolines, integrase inhibitors acting prior to integration: a new mechanism of action for anti-integrase agents","volume":"78","author":"Bonnenfant","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2009.06.015_bib3","doi-asserted-by":"crossref","first-page":"7852","DOI":"10.1128\/JVI.02203-06","article-title":"Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3\u2032-azido-3\u2032-dideoxythymidine","volume":"81","author":"Brehm","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2009.06.015_bib4","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1073\/pnas.88.4.1339","article-title":"Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA","volume":"88","author":"Bushman","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.jviromet.2009.06.015_bib5","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1073\/pnas.90.8.3428","article-title":"Domains of the integrase protein of human immunodeficiency virus type 1 responsible for polynucleotidyl transfer and zinc binding","volume":"90","author":"Bushman","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.jviromet.2009.06.015_bib6","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1177\/135965350801300710","article-title":"Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy","volume":"13","author":"Buzon","year":"2008","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.jviromet.2009.06.015_bib7","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1128\/JVI.70.1.651-657.1996","article-title":"Conserved sequences in the carboxyl terminus of integrase that are essential for human immunodeficiency virus type 1 replication","volume":"70","author":"Cannon","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2009.06.015_bib8","first-page":"S6","article-title":"Specific mutations related to resistance to HIV-1 integrase inhibitors are associated with reverse transcriptase mutations in HAART-treated patients","volume":"12","author":"Ceccherini-Silberstein","year":"2007","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.jviromet.2009.06.015_bib9","series-title":"15th Conference on Retroviruses and Opportunistic Infections","article-title":"Novel HIV-1 integrase mutations, found as minority quasispecies in patients naive to integrase inhibitors, are associated with decreased susceptibility to integrase inhibitors in vitro","author":"Ceccherini-Silberstein","year":"2008"},{"key":"10.1016\/j.jviromet.2009.06.015_bib10","series-title":"14th Conference on Retroviruses and Opportunistic Infections","article-title":"Results of BENCHMRK-1, a Phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus","author":"Cooper","year":"2007"},{"key":"10.1016\/j.jviromet.2009.06.015_bib11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1056\/NEJMoa0708978","article-title":"Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection","volume":"359","author":"Cooper","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jviromet.2009.06.015_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.qai.0000233308.82860.2f","article-title":"Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients","volume":"43","author":"DeJesus","year":"2006","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jviromet.2009.06.015_bib13","doi-asserted-by":"crossref","first-page":"6837","DOI":"10.1128\/JVI.02820-06","article-title":"Mutations in human immunodeficiency virus type 1 RNaseH primer grip enhance 3\u2032-azido-3\u2032-deoxythymidine resistance","volume":"81","author":"Delviks-Frankenberry","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2009.06.015_bib14","doi-asserted-by":"crossref","first-page":"10943","DOI":"10.1073\/pnas.0804660105","article-title":"HIV-1 reverse transcriptase connection subdomein mutations reduce template RNA degradation and enhance AZT excision","volume":"105","author":"Delviks-Frankenberry","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.jviromet.2009.06.015_bib15","doi-asserted-by":"crossref","first-page":"6361","DOI":"10.1128\/JVI.66.11.6361-6369.1992","article-title":"Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro","volume":"66","author":"Engelman","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2009.06.015_bib16","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/0092-8674(91)90297-C","article-title":"HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer","volume":"67","author":"Engelman","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.jviromet.2009.06.015_bib17","series-title":"16th Conference on Retroviruses and Opportunistic Infections","article-title":"Switching from stable lopinavir\/ritonavir-based to raltegravir-based combination ART resulted in a superior lipid profile at week 12 but did not demonstrate non-inferior virologic efficacy at week 24","author":"Eron","year":"2009"},{"key":"10.1016\/j.jviromet.2009.06.015_bib18","doi-asserted-by":"crossref","first-page":"11244","DOI":"10.1073\/pnas.200139397","article-title":"HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase","volume":"97","author":"Espeseth","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.jviromet.2009.06.015_bib19","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1097\/00002030-200410210-00006","article-title":"Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360","volume":"18","author":"Fikkert","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.jviromet.2009.06.015_bib20","series-title":"48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Performance characteristics and validation of the PhenoSense HIV integrase assay","author":"Fransen","year":"2008"},{"key":"10.1016\/j.jviromet.2009.06.015_bib21","doi-asserted-by":"crossref","first-page":"10366","DOI":"10.1128\/JVI.00470-08","article-title":"Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors","volume":"82","author":"Goethals","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2009.06.015_bib22","first-page":"A11","article-title":"Resistance mutations in HIV-1 integrase selected with raltegravir or elvitegravir confer reduced susceptibility to a diverse panel of integrase inhibitors","volume":"13","author":"Goethals","year":"2008","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.jviromet.2009.06.015_bib23","doi-asserted-by":"crossref","first-page":"13040","DOI":"10.1073\/pnas.96.23.13040","article-title":"Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design","volume":"96","author":"Goldgur","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.jviromet.2009.06.015_bib24","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jama.296.7.827","article-title":"Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel","volume":"296","author":"Hammer","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jviromet.2009.06.015_bib25","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1126\/science.287.5453.646","article-title":"Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells","volume":"287","author":"Hazuda","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.jviromet.2009.06.015_bib26","series-title":"XVIth International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications","article-title":"Resistance to the HIV-integrase inhibitor raltegravir: analysis of protocol 005, a Phase 2 study in patients with triple-class resistant HIV-1 infection","author":"Hazuda","year":"2007"},{"key":"10.1016\/j.jviromet.2009.06.015_bib27","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1126\/science.1098632","article-title":"Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques","volume":"305","author":"Hazuda","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.jviromet.2009.06.015_bib28","series-title":"14th Conference on Retroviruses and Opportunistic Infections","article-title":"Quantification of resistance to protease, reverse transcriptase, and integrase inhibitors based on 3\u2032Gag\/PR\/RT\/INT-recombinant viruses: a useful tool in the upcoming era of integrase inhibitors","author":"Henry","year":"2008"},{"key":"10.1016\/j.jviromet.2009.06.015_bib29","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1128\/AAC.42.2.269","article-title":"A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs","volume":"42","author":"Hertogs","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jviromet.2009.06.015_bib30","first-page":"138","article-title":"Update of the drug resistance mutations in HIV-1","volume":"16","author":"Johnson","year":"2008","journal-title":"Top. HIV Med."},{"key":"10.1016\/j.jviromet.2009.06.015_bib31","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1128\/AAC.39.2.320","article-title":"Inhibition of human immunodeficiency virus integrase by bis-catechols","volume":"39","author":"LaFemina","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jviromet.2009.06.015_bib32","first-page":"S28","article-title":"Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance","volume":"11","author":"Lataillade","year":"2007","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.jviromet.2009.06.015_bib33","series-title":"48th ICAAC","article-title":"STARTMRK, a phase III study of the safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-na\u00efve HIV-infected patients","author":"Lennox","year":"2008"},{"key":"10.1016\/j.jviromet.2009.06.015_bib34","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1093\/nar\/22.20.4125","article-title":"Characterization of the minimal DNA-binding domain of the HIV integrase protein","volume":"22","author":"Lutzke","year":"1994","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jviromet.2009.06.015_bib35","series-title":"16th International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications","article-title":"Biochemical characterization of the effect of mutations selected in HIV-1 integrase gene associated with failure to raltegravir (MK-0518)","author":"Malet","year":"2007"},{"key":"10.1016\/j.jviromet.2009.06.015_bib36","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/QAI.0b013e31802b4956","article-title":"Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals","volume":"43","author":"Markowitz","year":"2006","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jviromet.2009.06.015_bib37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/QAI.0b013e318157131c","article-title":"Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study","volume":"46","author":"Markowitz","year":"2007","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jviromet.2009.06.015_bib38","series-title":"XVIth International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications","article-title":"Resistance and cross-resistance to first-generation integrase inhibitors: insights from a Phase II study of elvitegravir (GS-9137)","author":"McColl","year":"2007"},{"key":"10.1016\/j.jviromet.2009.06.015_bib39","first-page":"S5","article-title":"HIV-1 integrase sequence variation and covariation","volume":"12","author":"Myers","year":"2007","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.jviromet.2009.06.015_bib40","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1073\/pnas.0609642104","article-title":"Mutations in the connection domain of HIV-1 reverse transcriptase increase 3\u2032-azido-3\u2032-deoxythymidine resistance","volume":"104","author":"Nikolenko","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.jviromet.2009.06.015_bib41","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0960-9822(02)00952-1","article-title":"New class of HIV integrase inhibitors that block viral replication in cell culture","volume":"12","author":"Pannecouque","year":"2002","journal-title":"Curr. Biol."},{"key":"10.1016\/j.jviromet.2009.06.015_bib42","series-title":"6th European HIV Resistance Workshop 2008","article-title":"Preliminary biological cutoffs for GS-9137 and MK-0518 integrase inhibitors derived from clonal phenotypic analysis","author":"Rondelez","year":"2008"},{"key":"10.1016\/j.jviromet.2009.06.015_bib43","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1021\/jm0600139","article-title":"Novel HIV-1 integrase inhibitors derived from quinolone antibiotics","volume":"49","author":"Sato","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jviromet.2009.06.015_bib44","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1128\/JVI.01534-07","article-title":"Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303\/GS-9137)","volume":"82","author":"Shimura","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2009.06.015_bib45","series-title":"14th Conference on Retroviruses and Opportunistic Infections","article-title":"Performance of prototype integrase genotyping reagents for analysis of diverse HIV-1 strains","author":"Smith","year":"2008"},{"key":"10.1016\/j.jviromet.2009.06.015_bib46","series-title":"14th Conference on Retroviruses and Opportunistic Infections","article-title":"Results of BENCHMRK-1, a Phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus","author":"Steigbigel","year":"2007"},{"key":"10.1016\/j.jviromet.2009.06.015_bib47","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMoa0708975","article-title":"Raltegravir with optimized background therapy for resistant HIV-1 infection","volume":"359","author":"Steigbigel","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jviromet.2009.06.015_bib48","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.2146\/news070092","article-title":"Integrase inhibitor gains FDA approval","volume":"64","author":"Traynor","year":"2007","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.jviromet.2009.06.015_bib49","first-page":"S7","article-title":"Low level of baseline resistance to integrase inhibitors L731,988 and L870,810 in randomly selected subtype B and non-B HIV-1 strains","volume":"12","author":"Van Baelen","year":"2007","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.jviromet.2009.06.015_bib50","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1097\/QAD.0b013e32830f9703","article-title":"Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility","volume":"22","author":"Van Baelen","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.jviromet.2009.06.015_bib51","series-title":"6th European HIV Resistance Workshop 2008","article-title":"Identification of residues in HIV-1 integrase, RNAseH and the RT connection domain associated with the presence of thymidine analogue-associated resistance","author":"Van Eygen","year":"2008"},{"key":"10.1016\/j.jviromet.2009.06.015_bib52","first-page":"26","article-title":"HIV-1 integration: an interplay between HIV-1 integrase, cellular and viral proteins","volume":"7","author":"Van Maele","year":"2005","journal-title":"AIDS Rev."},{"key":"10.1016\/j.jviromet.2009.06.015_bib53","doi-asserted-by":"crossref","first-page":"38045","DOI":"10.1074\/jbc.M205842200","article-title":"DNA-induced polymerization of HIV-1 integrase analyzed with fluorescence fluctuation spectroscopy","volume":"277","author":"Vercammen","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jviromet.2009.06.015_bib54","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1021\/jm025553u","article-title":"Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells","volume":"46","author":"Zhuang","year":"2003","journal-title":"J. Med. Chem."}],"container-title":["Journal of Virological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166093409003024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166093409003024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T20:18:53Z","timestamp":1685045933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166093409003024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S0166093409003024"],"URL":"https:\/\/doi.org\/10.1016\/j.jviromet.2009.06.015","relation":{},"ISSN":["0166-0934"],"issn-type":[{"value":"0166-0934","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}